AK112 for untreated advanced kidney cancer
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This study tests a new drug called AK112 for people with advanced or metastatic clear cell kidney cancer who have not had any prior treatment. The goal is to see if AK112 can shrink tumors or slow cancer growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- Your kidney cancer must be the clear cell type (the most common kind).
- You must not have had any prior treatment for advanced kidney cancer.
- You must have a performance status of 0 or 1 (fully active or able to do light work).
- You must not have an untreated autoimmune disease or brain metastases that require steroids.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new drug called AK112 (Yiwoxidan Anti) in people with advanced clear cell kidney cancer who cannot take TKI medications. The goal is to see if it is safe and effective.
This trial tests a new immunotherapy drug, AK112, for people with a specific type of lung cancer (non-squamous) that has certain genetic changes and has stopped responding to targeted therapy. The goal is to see if AK112 can help when targeted treatments no longer work.
This trial tests a new drug, PF-08634404, alone or with other cancer treatments, for adults with advanced kidney cancer that has not been treated before. It aims to see if the drug can help shrink tumors or stop them from growing.
This study tests a new drug called AK112 (a combination antibody targeting two proteins that help tumors grow) after surgery for liver cancer that has a high chance of returning. The goal is to see if it can prevent the cancer from coming back.
This trial tests a new drug, AK112, combined with chemotherapy for people with advanced non-squamous non-small cell lung cancer that has spread to the lining of the lung (malignant pleural effusion). The goal is to see if this combination helps shrink tumors and improve outcomes.
This study tests a new drug called AK112 (a bispecific antibody that blocks both PD-1 and VEGF) as a consolidation treatment to help prevent your limited-stage small cell lung cancer from coming back after you've finished chemoradiation. It's for people whose cancer has not grown following concurrent chemotherapy and radiation.
Hear when a new Renal Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.